ZBIO Stock Analysis: Buy, Sell, or Hold?
ZBIO - Zenas BioPharma, Inc. Common Stock
$18.37
-2.51 (-12.02%)
▼
HOLD
LOW Confidence
Last Updated: January 30, 2026
Earnings: Feb 11, 2026
10d
Get Alerted When ZBIO Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: ZBIO shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
📊 HOLD: ZBIO shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
In-depth Analysis How we analyze
Valuation Analysis: ZBIO is currently trading at $18.37, which is considered slightly low relative to its 30-day fair value range of $15.66 to $34.95.
Technical Outlook: Technically, ZBIO is in a uptrend. The price is currently testing key support at $19.00. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 12.0% recently.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $43.57 (+108.7%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, ZBIO is in a uptrend. The price is currently testing key support at $19.00. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 12.0% recently.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $43.57 (+108.7%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Fair Price Range
$15.66 -
$34.95
Company Quality Score
52/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
82.1%
Protect Your Profits
Holding ZBIO? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Options cheap (IV 0th percentile)
- NEUTRAL: Mixed technical signals (45/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-12.0%)
- BULLISH: Trading 108.7% below Wall St target ($43.57)
- CAUTION: Recommendation downgraded due to -8.6% 5-day decline
Fair Price Analysis
30-Day Fair Range
$15.66 -
$34.95
Current vs Fair Value
SLIGHTLY LOW
Expected Move (7 Days)
±$2.52
(13.7%)
Support & Resistance Levels
Support Level
$19.00
Resistance Level
$22.70
Current Trend
Uptrend
Fundamental Context
Forward P/E (Next Year Est.)
-4.75
Wall Street Target
$43.57
(+108.7%)
Last updated: January 30, 2026 9:45 PM ET
Data refreshes hourly during market hours. Next update: 10:45 PM
Data refreshes hourly during market hours. Next update: 10:45 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ZBIO showing a specific setup today?
Insider Activity (6 Months)
7
Buys
0
Sells
+
Net
INSIDERS BUYING
Recent Transactions
Jason Raleigh Nunn
BUY
63158 shares
2025-10-09
Patrick G Enright
BUY
11990 shares
2025-10-09
Patrick G Enright
BUY
105265 shares
2025-10-09
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$22 | 60 HOLD |
|
ARGX
argenx NV ADR |
STRONG BUY
22 analysts |
$1035 | 58 HOLD |
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$83 | 57 HOLD |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$33 | 60 HOLD |
|
MRUS
Merus BV |
STRONG BUY
17 analysts |
$97 | 55 HOLD |
Advanced ZBIO Option Strategies
Professional options setups generated by AI based on today's ZBIO price and gamma walls.
